LPCN - Lipocine Is One To Watch Based On Possible FDA Approval Of TLANDO And NASH Data
- Lipocine has obtained positive results in a phase 2 study using its drug LPCN1144 for the treatment of patients with NASH.
- TLANDO is being resubmitted to the FDA as a Class 1 resubmission with 2 months review time; possible FDA approval expected on January 28, 2022.
- It is estimated that the global NASH market could be worth $20 billion by 2027.
- It is said that the global Hypogonadism market could reach $3.233 billion by 2023.
- Lipocine Inc. had unrestricted cash, cash equivalents, and marketable investments of $38.7 million as of September 30, 2021; enough cash until at least September 30, 2022.
For further details see:
Lipocine Is One To Watch Based On Possible FDA Approval Of TLANDO And NASH Data